scholarly journals Proteasomal Inhibition Potentiates Latent HIV Reactivation

2020 ◽  
Vol 36 (10) ◽  
pp. 800-807
Author(s):  
Daniele C. Cary ◽  
B. Matija Peterlin
Author(s):  
Sahana Pai ◽  
Jayesh Mudgal ◽  
B. Venkatesh Kamath ◽  
K. Sreedhara Ranganath Pai

AbstractHuman immunodeficiency virus-1 (HIV-1) infection remains to be one of the major threats throughout the world. Many researchers are working in this area to find a cure for HIV-1. The group of the FDA approved drugs which are currently used against HIV-1 in the clinical practice include nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase inhibitors (InIs), and protease inhibitors (PIs). Fixed dose combinations (FDCs) of these drugs are available and are used as per the anti-retroviral therapy (ART) guidelines. Despite these, unfortunately, there is no cure for HIV1 infection to date. The present review is focused upon describing the importance of a post-transcriptional regulatory protein “Rev”, responsible for latent HIV-1 infection as a possible, and promising therapeutic target against HIV-1.


iScience ◽  
2021 ◽  
pp. 102940
Author(s):  
Neha Goswami ◽  
Yiyang Lu ◽  
Mikhail E. Kandel ◽  
Michael J. Fanous ◽  
Kathrin Bohn-Wippert ◽  
...  

2016 ◽  
Vol 103 ◽  
pp. 29-39 ◽  
Author(s):  
Ka C. Lee ◽  
Rebecca L. Bramley ◽  
Ian G. Cowell ◽  
Graham H. Jackson ◽  
Caroline A. Austin

Sign in / Sign up

Export Citation Format

Share Document